I can confirm it was a direct, open market purchase.
Look at the Form 4 - the transaction code in Column 3 is P - a purchase, not A which would be Acquisition which are what your non-open market purchases get tagged with. Also, the price in Column 4 is $3.30/share - the market price. Non-open market trades may have a price below current market price or $0 if it is an award.
See Column 6 in the table - D = Direct.
No notes are indicated, which would provide explanatory information if it was anything other than an open market purchase or other indirect ownership scenario.
Good questions, unfortunately I don't have answers.
Trying to see where the growth component is here. The balance sheet looks clean, the insider buying looks good. But all I see is a company that is teetering on breakeven for the full year. Based on the full year analyst estimate of 8 cents, that's not doable given the two quarters already posted and the estimate for this/next quarters. So we're looking at 4 cents/share for the year based on the quarterly estimates shown. Is this worth a PE of 45 or 50? We could just as easily be looking at a loss for the year.
I want to like/buy it, but I don't see the growth/catalyst.
Anyone who can provide the key selling points here?
True, but I can't help but think the price rise over past couple days is simply going with the entire market for the most part - which I won't complain about. Until we get the next earnings report, I don't see the fundamental reasoning for the rise. True, FDA approval is positive. But, when do we see profitability? We're now sitting on $150 million debt. When does the red ink stop? I also don't want to hear about one-time non-cash charges and non-GAAP earnings. I want to see clean profitability. Until that happens, I think it's a crapshoot. Just my view.
Considering what the stock did yesterday, pretty hard to believe there are no posts here.
Clearly some momentum has returned. Maybe folks have figured out that most other parts of the market are overbought and MXWL can easily go to $15 and be fairly priced.
Slow/continued accumulation of shares during the past year - and the stock has more than doubled over that time period. Definitely a positive sign.
Robin Raina sold 324,132 shares on Friday at $17.50/share
Note the remarks section of the filing:
Proceeds from open market sale to be used for payment of income taxes related to 2012 exercise of stock options.
Yes, it is interesting.
Here - they did it again past couple days shown in filings yesterday.
Joel Perlin purchased 240,000 shares for less than 50 cents/share on May 9.
He was also received warrants for another 120,000 shares at $1/share.